MOTOR-ACTIVITY FOLLOWING THE ADMINISTRATION OF SELECTIVE D-1 AND D-2 DOPAMINERGIC DRUGS TO NORMAL COMMON MARMOSETS

被引:31
作者
LOSCHMANN, PA
SMITH, LA
LANGE, KW
JAEHNIG, P
JENNER, P
MARSDEN, CD
机构
[1] NATL HOSP,INST NEUROL,DEPT CLIN NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND
[2] KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,PARKINSONS DIS SOC,EXPTL RES LABS,LONDON SW3 6LX,ENGLAND
[3] SCHERING AG,RES LABS,W-1000 BERLIN 65,GERMANY
[4] AFB COMSTAT GMBH BERLIN,EUROPACTR,W-1000 BERLIN 15,GERMANY
基金
英国惠康基金;
关键词
D-1; RECEPTORS; D-2; FUNCTIONAL INTERACTION; LOCOMOTOR ACTIVITY; COMMON MARMOSETS;
D O I
10.1007/BF02244422
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In normal common marmosets administration of the D-1/D-2 agonist apomorphine or the selective D-2 agonist quinpirole caused a dose-dependent increase in motor activity and induced stereotyped behaviour. Both the selective D-2 antagonist raclopride and the selective D-1 antagonist SCH 23390 inhibited normal locomotor activity and induced catalepsy. Quinpirole- and apomorphine-induced motor activity were potently inhibited by pretreatment with raclopride. The effects of quinpirole, but not apomorphine, were weakly inhibited by SCH 23390. The selective D-1 partial agonist SKF 38393 decreased motor activity and did not induce grooming, oral movements or other behaviours. SKF 38393 inhibited motor activity induced by the administration of quinpirole but did not alter apomorphine-induced motor behaviour. Locomotor activity in normal common marmosets appears to be mediated mainly via D-2 systems. In contrast to rodents, administration of SKF 38393 does not induce behavioural activation and there does not appear to be a facilitating effect of D-1 systems on D-2 function in the normal common marmoset. However, the ability of both SKF 38393 and SCH 23390 to inhibit quinpirole locomotor activity suggests some interaction between D-1 and D-2 systems to occur in this species.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 26 条
[1]   DOPAMINERGIC MECHANISMS IN HEMIPARKINSONIAN MONKEYS [J].
BARONE, P ;
BANKIEWICZ, KS ;
CORSINI, GU ;
KOPIN, IJ ;
CHASE, TN .
NEUROLOGY, 1987, 37 (10) :1592-1595
[2]   SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE [J].
BRAUN, A ;
FABBRINI, G ;
MOURADIAN, MM ;
SERRATI, C ;
BARONE, P ;
CHASE, TN .
JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (1-2) :41-50
[3]   PHARMACOLOGICAL EFFECTS OF A SPECIFIC DOPAMINE D-1 ANTAGONIST SCH-23390 IN COMPARISON WITH NEUROLEPTICS [J].
CHRISTENSEN, AV ;
ARNT, J ;
HYTTEL, J ;
LARSEN, JJ ;
SVENDSEN, O .
LIFE SCIENCES, 1984, 34 (16) :1529-1540
[4]   REVIEW - D1 DOPAMINE RECEPTOR - THE SEARCH FOR A FUNCTION - A CRITICAL-EVALUATION OF THE D1/D2 DOPAMINE RECEPTOR CLASSIFICATION AND ITS FUNCTIONAL IMPLICATIONS [J].
CLARK, D ;
WHITE, FJ .
SYNAPSE, 1987, 1 (04) :347-388
[5]  
DALLOLIO R, 1988, PSYCHOPHARMACOLOGY, V95, P381
[6]   CY-208-243 - A UNIQUE COMBINATION OF ATYPICAL OPIOID ANTINOCICEPTION AND D1 DOPAMINOMIMETIC PROPERTIES [J].
FOOTE, RW ;
BUSCHER, HH ;
ROMER, D ;
MAURER, R ;
ENZ, A ;
GAHWILER, BH ;
SHEARMAN, GT ;
SEILER, MP ;
WUTHRICH, H .
LIFE SCIENCES, 1988, 42 (02) :137-152
[7]   THE D1-DOPAMINE RECEPTOR ANTAGONIST, SCH 23390 REDUCES LOCOMOTOR-ACTIVITY AND REARING IN RATS [J].
HOFFMAN, DC ;
BENINGER, RJ .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1985, 22 (02) :341-342
[8]   DOPAMINE-MEDIATED BEHAVIORS PRODUCED IN NAIVE MICE BY BROMOCRIPTINE PLUS SKF-38393 [J].
JACKSON, DM ;
ROSS, SB ;
HASHIZUME, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (03) :221-223
[9]   MULTIPLE RECEPTORS FOR DOPAMINE [J].
KEBABIAN, JW ;
CALNE, DB .
NATURE, 1979, 277 (5692) :93-96
[10]   STEREOTYPED BEHAVIOR IN RESPONSE TO THE SELECTIVE D-2 DOPAMINE RECEPTOR AGONIST RU-24213 IS ENHANCED BY PRETREATMENT WITH THE SELECTIVE D-1 AGONIST SK-AND-F 38393 [J].
MASHURANO, M ;
WADDINGTON, JL .
NEUROPHARMACOLOGY, 1986, 25 (08) :947-949